Literature DB >> 26638884

Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies.

Reza Salarinia, Amirhossein Sahebkar, Mostafa Peyvandi, Hamid Reza Mirzaei, Mahmoud Reza Jaafari, Maryam Matbou Riahi, Hamed Ebrahimnejad, Javid Sadri Nahand, Jamshid Hadjati, Mobina Ostadi Asrami, Sara Fadaei, Rasoul Salehi1, Hamed Mirzaei2.   

Abstract

Epigenetic modifications determine phenotypic characteristics in a reversible, stable and genotype-independent manner. Epigenetic modifications mainly encompass CpG island methylation and histone modifications, both being important in the pathogenesis of malignancies. The reversibility of epigenetic phenomenon provides a suitable therapeutic option that is reactivation of epigenetically silenced tumor-suppressor genes. Inhibition of DNA methyltransferase, histone deacetylase and Aurora B kinase, individually or collectively, could feasibly prevent or reverse the impact of epigenetic silencing. MicroRNAs [miRNAs] are an important layer of epigenetic controlling of gene expression, and serve as diagnostic and prognostic biomarkers as well as treatment targets for several types of cancer. miRNAs are involved inepigenetically silencing or activation of genes, tumor suppressor genes and oncogenes, and their modulation opens new horizons for designing novel cancer therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26638884     DOI: 10.2174/1568009616666151207110143

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  24 in total

Review 1.  Epidrugs: targeting epigenetic marks in cancer treatment.

Authors:  Cristiana Libardi Miranda Furtado; Maria Claudia Dos Santos Luciano; Renan Da Silva Santos; Gilvan Pessoa Furtado; Manoel Odorico Moraes; Claudia Pessoa
Journal:  Epigenetics       Date:  2019-07-13       Impact factor: 4.528

Review 2.  Glioblastoma: exosome and microRNA as novel diagnosis biomarkers.

Authors:  L Saadatpour; E Fadaee; S Fadaei; R Nassiri Mansour; M Mohammadi; S M Mousavi; M Goodarzi; J Verdi; H Mirzaei
Journal:  Cancer Gene Ther       Date:  2016-11-11       Impact factor: 5.987

3.  Circulating microRNA: a new candidate for diagnostic biomarker in neuroblastoma.

Authors:  M Mohammadi; M Goodarzi; M R Jaafari; H R Mirzaei; H Mirzaei
Journal:  Cancer Gene Ther       Date:  2016-10-14       Impact factor: 5.987

Review 4.  The Story of Nanoparticles in Differentiation of Stem Cells into Neural Cells.

Authors:  Vajihe Asgari; Amir Landarani-Isfahani; Hossein Salehi; Noushin Amirpour; Batool Hashemibeni; Saghar Rezaei; Hamid Bahramian
Journal:  Neurochem Res       Date:  2019-11-12       Impact factor: 3.996

5.  The effect of oxamflatin on the E-cadherin expression in gastric cancer cell line.

Authors:  E Faghihloo; Y Araei; M Mohammadi; H Mirzaei; H R Mohammadi; T Mokhtari-Azad
Journal:  Cancer Gene Ther       Date:  2016-10-21       Impact factor: 5.987

Review 6.  Imaging techniques: new avenues in cancer gene and cell therapy.

Authors:  Z Saadatpour; A Rezaei; H Ebrahimnejad; B Baghaei; G Bjorklund; M Chartrand; A Sahebkar; H Morovati; H R Mirzaei; H Mirzaei
Journal:  Cancer Gene Ther       Date:  2016-11-11       Impact factor: 5.987

7.  Circulating microRNA-192 as a diagnostic biomarker in human chronic lymphocytic leukemia.

Authors:  S Fathullahzadeh; H Mirzaei; M A Honardoost; A Sahebkar; M Salehi
Journal:  Cancer Gene Ther       Date:  2016-09-23       Impact factor: 5.987

8.  Up-regulation of microRNA-202-3p in first trimester placenta of pregnancies destined to develop severe preeclampsia, a pilot study.

Authors:  Krishna Singh; John Williams; Jordan Brown; Erica T Wang; Bora Lee; Tania L Gonzalez; Jinrui Cui; Mark O Goodarzi; Margareta D Pisarska
Journal:  Pregnancy Hypertens       Date:  2017-05-08       Impact factor: 2.899

Review 9.  Cardiac complications in inherited mitochondrial diseases.

Authors:  Mohaddeseh Behjati; Mohammad Reza Sabri; Masood Etemadi Far; Majid Nejati
Journal:  Heart Fail Rev       Date:  2021-03       Impact factor: 4.214

10.  Alterations in The Plasma Expression of mir-15b, mir-195 and the Tumor-Suppressor Gene DLEU7 in Patients with B-Cell Chronic Lymphocytic Leukemia.

Authors:  Malihe Bagheri; Behzad Khansarinejad; Ghasem Mosayebi; Alireza Moradabadi; Mahdieh Mondanizadeh
Journal:  Rep Biochem Mol Biol       Date:  2021-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.